查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1890923

壞死性筋膜炎市場按類型、治療方法、給藥途徑、解剖部位、最終用戶、通路、風險因素、年齡層和地區分類

Necrotizing Fasciitis Market, By Type, By Treatment Modality, By Route of Administration, By Anatomical Location, By End User, By Distribution Channel, By Risk-Factor, By Age Group, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 151 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

壞死性筋膜炎市場預計在 2025 年達到 12.1 億美元，預計到 2032 年將達到 21.4 億美元，2025 年至 2032 年的複合年成長率為 8.5%。

報告內容 報告詳情
基準年： 2024 2025年市場規模： 12.1億美元
歷史數據時期： 2020年至2024年 預測期： 2025年至2032年
預測期（2025-2032年）複合年成長率： 8.50% 2032 年的預測值： 21.4億美元

壞死性筋膜炎是最嚴重、進展最快的軟組織感染疾病之一，其特徵是筋膜和周圍組織大面積壞死，需要立即進行醫療干預以防止致命後果。

這種罕見但嚴重的細菌感染疾病，常被稱為“食肉病”，會影響皮膚深層和皮下組織。即使採取積極的治療通訊協定，死亡率也高達20%至40%。全球壞死性筋膜炎市場涵蓋了診斷工具、治療性介入、手術器械和輔助護理技術等一系列旨在對抗這種危及生命的疾病的綜合生態系統。

市場成長的促進因素包括醫療專業人員意識的提高、快速診斷技術的進步以及標靶抗菌療法的開發。主要市場細分包括診斷解決方案（如影像技術和檢測套組）、治療產品（如頻譜抗生素和免疫球蛋白療法）以及傷口清創手術所需的外科器械。

此外，糖尿病和免疫力缺乏疾病的日益普遍增加了嚴重軟組織感染疾病的風險，開發中國家醫療保健支出不斷增加，以及持續開展的旨在改善患者預後和縮短治療時間的研究工作，也都在影響著市場格局。

市場動態

全球壞死性筋膜炎市場主要受幾個強力的因素驅動，這些因素共同推動市場擴張和創新：全球糖尿病和其他免疫力缺乏疾病的發病率不斷上升，顯著增加了嚴重軟組織感染疾病的風險，並擴大了需要特殊治療性介入的患者群體。

醫療保健意識的提高和診斷能力的提升使得早期發現和早期療育成為可能，這對患者的生存和康復結果具有決定性影響。快速診斷工具的技術進步，包括就地檢驗設備和先進成像設備，促進了壞死性筋膜炎的早期識別，從而推動了市場對創新診斷解決方案的需求。

此外，新型抗菌藥物和聯合治療的研發正在應對日益嚴重的抗生素抗藥性問題，而新興經濟體醫療保健支出的成長也有助於擴大市場准入。然而，該市場面臨著許多限制因素，包括疾病的罕見性限制了大規模臨床試驗的開展，延緩了研究進展；以及與緊急治療通訊協定和長期住院相關的高昂費用，給患者和醫療保健系統都帶來了經濟負擔。

診斷的複雜性往往會導致治療啟動延遲，從而造成患者預後不良，並為醫療機構帶來訴訟風險。此外，基層醫療醫師和急診室工作人員缺乏相關意識也會導致誤診和延誤識別。儘管存在這些挑戰，但在開發快速診斷平台、創建標靶治療方案、擴展遠端照護能力以進行遠距會診和診斷以及建立專科治療中心等領域仍存在著巨大的機會。

本次調查的主要特點

  • 本報告對全球壞死性筋膜炎市場進行了詳細分析，以 2024 年為基準年，給出了預測期（2025-2032 年）內的市場規模（十億美元）和復合年成長率（%）。
  • 該報告還重點介紹了各個細分市場的潛在商機，並概述了該市場具有吸引力的投資提案矩陣。
  • 該研究還提供了有關市場促進因素、阻礙因素、機會、新產品發布或核准、市場趨勢、區域展望以及主要參與者採取的競爭策略的重要見解。
  • 本報告根據以下參數介紹了全球壞死性筋膜炎市場主要企業的概況：公司概況、產品系列、主要亮點、財務表現和策略。
  • 本報告的研究結果將使負責人和企業經營團隊能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
  • 這份全球壞死性筋膜炎市場報告的目標受眾是該行業的各類相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
  • 相關人員可以透過用於分析全球壞死性筋膜炎市場的各種策略矩陣輕鬆做出決策。

目錄

第1章 研究目標與前提條件

  • 調查目的
  • 先決條件
  • 簡稱

第2章 市場範圍

  • 報告概述
    • 市場定義和範圍
  • 執行摘要

第3章 市場動態、監管與趨勢分析

  • 市場動態
  • 促進要素
  • 抑制因素
  • 機會
  • 影響分析
  • 重大進展
  • 法規環境
  • 產品上市及核准
  • PEST分析
  • 波特分析
  • 併購趨勢
  • 產業趨勢

4. 2020-2032年全球壞死性筋膜炎市場（按類型分類）

  • 多重微生物（I 型）
  • 單微生物（II 型）
  • 梭菌性/氣性壞疽（III型）
  • 其他（例如，真菌性行為感染、非典型病原體）

5. 2020-2032年全球壞死性筋膜炎市場（依治療方法）

  • 外科/介入治療（如切除術、切除手術）
  • 抗生素/抗菌療法
  • 輔助性治療（例如，高壓氧氣療法、創傷護理設備）
  • 其他（輔助治療）

6. 2020-2032年全球壞死性筋膜炎市場（依給藥途徑分類）

  • 腸外
  • 口服

7. 2020-2032年全球壞死性筋膜炎市場（依解剖部位分類）

  • 上肢
  • 下肢
  • 會陰部和生殖器（福尼爾壞疽）
  • 頭部和頸部
  • 身體軀幹和腹壁

8. 2020-2032年全球壞死性筋膜炎市場（依最終用戶分類）

  • 醫院和診所
  • 門診手術中心
  • 復健中心
  • 診斷中心
  • 學術和研究機構
  • 家庭醫療保健

9. 2020-2032年全球壞死性筋膜炎市場依通路分類

  • 醫院藥房
  • 零售藥房
  • 網路藥局/網路藥局

第10章 全球壞死性筋膜炎市場風險因子分析（2020-2032年）

  • 糖尿病
  • 肥胖
  • 免疫力缺乏/腫瘤患者
  • 周邊血管疾病/慢性腎臟病
  • 靜脈注射毒品者/酒精成癮

第11章 2020-2032年全球壞死性筋膜炎市場（依年齡層分類）

  • 嬰兒和兒童（18 歲以下）
  • 成年人（18-64歲）
  • 老年人（65歲以上）

第12章 2020-2032年全球壞死性筋膜炎市場（按地區分類）

  • 北美洲
    • 美國
    • 加拿大
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 墨西哥
    • 其他拉丁美洲國家
  • 歐洲
    • 德國
    • 英國
    • 西班牙
    • 法國
    • 義大利
    • 俄羅斯
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 韓國
    • ASEAN
    • 亞太其他地區
  • 中東
    • 海灣合作理事會國家
    • 以色列
    • 其他中東國家
  • 非洲
    • 南非
    • 北非
    • 中非

第13章 競爭格局

  • Pfizer Inc
  • Merck and Co Inc
  • GlaxoSmithKline plc
  • Novartis AG
  • Bayer AG
  • Abbott Laboratories
  • Baxter International Inc
  • Melinta Therapeutics LLC
  • Atox Bio Inc
  • Wound Care Technologies Inc
  • ConvaTec Group Plc
  • Smith and Nephew plc
  • Molnlycke Health Care AB
  • 3M Company
  • Becton Dickinson and Company

第14章 分析師建議

  • 機會
  • 分析師觀點
  • Coherent Opportunity Map

第15章 參考文獻與調查方法

  • 參考
  • 調查方法
  • 關於出版商
簡介目錄
Product Code: CMI8934

Necrotizing Fasciitis Market is estimated to be valued at USD 1.21 Bn in 2025 and is expected to reach USD 2.14 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.5% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 1.21 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 8.50% 2032 Value Projection: USD 2.14 Bn

Necrotizing fasciitis represents one of the most critical and rapidly progressive soft tissue infections, characterized by extensive necrosis of the fascia and surrounding tissues, demanding immediate medical intervention to prevent fatal outcomes.

This rare but severe bacterial infection, often termed as flesh-eating disease, affects the deep layers of skin and subcutaneous tissues, with mortality rates ranging from 20% to 40% despite aggressive treatment protocols. The global necrotizing fasciitis market encompasses a comprehensive ecosystem of diagnostic tools, therapeutic interventions, surgical instruments, and supportive care technologies designed to combat this life-threatening condition.

The market's evolution is driven by increasing awareness among healthcare professionals, advancements in rapid diagnostic techniques, and the development of targeted antimicrobial therapies. Key market segments include diagnostic solutions such as imaging technologies and laboratory testing kits, therapeutic products including broad-spectrum antibiotics and immunoglobulin treatments, and surgical instruments essential for debridement procedures.

The market landscape is further influenced by the growing prevalence of diabetes and immunocompromised conditions that predispose patients to severe soft tissue infections, alongside rising healthcare expenditure in developing economies and continuous research initiatives focused on improving patient outcomes and reducing treatment timelines.

Market Dynamics

The global necrotizing fasciitis market is primarily driven by several compelling factors that collectively fuel market expansion and innovation. The increasing incidence of diabetes mellitus and other immunocompromising conditions worldwide significantly elevates the risk of severe soft tissue infections, creating a larger patient population requiring specialized treatment interventions.

Rising healthcare awareness and improved diagnostic capabilities enable earlier detection and intervention, which is crucial for patient survival and recovery outcomes. Technological advancements in rapid diagnostic tools, including point-of-care testing devices and advanced imaging modalities, facilitate quicker identification of necrotizing fasciitis, thereby driving market demand for innovative diagnostic solutions.

Additionally, the development of novel antimicrobial agents and combination therapies addresses the growing concern of antibiotic resistance, while increased healthcare spending in emerging economies expands market accessibility. However, the market faces significant restraints including the rarity of the condition, which limits large-scale clinical trials and slows research progress, alongside the high costs associated with emergency treatment protocols and extended hospital stays that create financial barriers for patients and healthcare systems.

The complexity of diagnosis often leads to delayed treatment initiation, resulting in poor patient outcomes and potential litigation concerns for healthcare providers. Furthermore, limited awareness among primary care physicians and emergency department staff can contribute to misdiagnosis or delayed recognition. Despite these challenges, substantial opportunities exist in developing rapid diagnostic platforms, creating targeted therapeutic solutions, expanding telemedicine capabilities for remote consultation and diagnosis, and establishing specialized treatment centers.

Key Features of the Study

  • This report provides in-depth analysis of the global necrotizing fasciitis market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global necrotizing fasciitis market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Pfizer Inc, Merck and Co Inc, GlaxoSmithKline plc, Novartis AG, Bayer AG, Abbott Laboratories, Baxter International Inc, Melinta Therapeutics LLC, Atox Bio Inc, Wound Care Technologies Inc, ConvaTec Group Plc, Smith and Nephew plc, Molnlycke Health Care AB, 3M Company, and Becton Dickinson and Company
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global necrotizing fasciitis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global necrotizing fasciitis market

Market Segmentation

  • Type Insights (Revenue, USD Bn, 2020 - 2032)
    • Polymicrobial (Type I)
    • Monomicrobial (Type II)
    • Clostridial / Gas gangrene (Type III)
    • Others (e.g., Fungal necrotizing infections, atypical pathogens)
  • Treatment Modality Insights (Revenue, USD Bn, 2020 - 2032)
    • Surgical/interventional (e.g., debridement, amputation)
    • Antibiotic/antimicrobial therapy
    • Adjunctive therapies (e.g., hyperbaric oxygen, wound-care devices)
    • Other (Supportive care)
  • Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
    • Parenteral
    • Oral
  • Anatomical Location Insights (Revenue, USD Bn, 2020 - 2032)
    • Upper Extremities
    • Lower Extremities
    • Perineal and Genital (Fournier's Gangrene)
    • Head and Neck
    • Torso and Abdominal Wall
  • End User Insights (Revenue, USD Bn, 2020 - 2032)
    • Hospitals and Clinics
    • Ambulatory Surgical Centers
    • Rehabilitation Centers
    • Diagnostic Centers
    • Academic and Research Institutes
    • Home Healthcare
  • Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
    • Hospital pharmacies
    • Retail pharmacies
    • Online/epharmacy
  • Risk-factor Insights (Revenue, USD Bn, 2020 - 2032)
    • Diabetes mellitus
    • Obesity
    • Immunocompromised/oncology patients
    • Peripheral vascular disease/chronic kidney disease
    • Intravenous drug users/alcoholism
  • Age Group Insights (Revenue, USD Bn, 2020 - 2032)
    • Infants and children (< 18 years)
    • Adults (18-64 years)
    • Seniors (65+ years)
  • Regional Insights (Revenue, USD Bn, 2020 - 2032)
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
    • South Africa
    • North Africa
    • Central Africa
  • Key Players Insights
    • Pfizer Inc
    • Merck and Co Inc
    • GlaxoSmithKline plc
    • Novartis AG
    • Bayer AG
    • Abbott Laboratories
    • Baxter International Inc
    • Melinta Therapeutics LLC
    • Atox Bio Inc
    • Wound Care Technologies Inc
    • ConvaTec Group Plc
    • Smith and Nephew plc
    • Molnlycke Health Care AB
    • 3M Company
    • Becton Dickinson and Company

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Necrotizing Fasciitis Market, By Type
    • Global Necrotizing Fasciitis Market, By Treatment Modality
    • Global Necrotizing Fasciitis Market, By Route of Administration
    • Global Necrotizing Fasciitis Market, By Anatomical Location
    • Global Necrotizing Fasciitis Market, By End User
    • Global Necrotizing Fasciitis Market, By Distribution Channel
    • Global Necrotizing Fasciitis Market, By Risk-Factor
    • Global Necrotizing Fasciitis Market, By Age Group
    • Global Necrotizing Fasciitis Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Driver
  • Restraint
  • Opportunity
  • Impact Analysis
  • Key Developments
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario
  • Industry Trends

4. Global Necrotizing Fasciitis Market, By Type, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Polymicrobial (Type I)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Monomicrobial (Type II)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Clostridial / Gas gangrene (Type III)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Others (e.g., Fungal necrotizing infections, atypical pathogens)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Necrotizing Fasciitis Market, By Treatment Modality, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Surgical/interventional (e.g., debridement, amputation)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Antibiotic/antimicrobial therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Adjunctive therapies (e.g., hyperbaric oxygen, wound-care devices)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Other (Supportive care)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Necrotizing Fasciitis Market, By Route of Administration, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Parenteral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Necrotizing Fasciitis Market, By Anatomical Location, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Upper Extremities
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Lower Extremities
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Perineal and Genital (Fournier's Gangrene)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Head and Neck
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Torso and Abdominal Wall
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Necrotizing Fasciitis Market, By End User, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospitals and Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Ambulatory Surgical Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Rehabilitation Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Diagnostic Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Academic and Research Institutes
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Home Healthcare
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Necrotizing Fasciitis Market, By Distribution Channel, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospital pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Retail pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Online/epharmacy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

10. Global Necrotizing Fasciitis Market, By Risk-Factor, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Diabetes mellitus
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Obesity
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Immunocompromised/oncology patients
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Peripheral vascular disease/chronic kidney disease
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Intravenous drug users/alcoholism
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

11. Global Necrotizing Fasciitis Market, By Age Group, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Infants and children (< 18 years)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Adults (18-64 years)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Seniors (65+ years)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

12. Global Necrotizing Fasciitis Market, By Region, 2020 - 2032, Value (USD Bn)

  • Introduction
    • Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
    • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Treatment Modality, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Anatomical Location, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Risk-Factor, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Treatment Modality, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Anatomical Location, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Risk-Factor, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Treatment Modality, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Anatomical Location, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Risk-Factor, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Treatment Modality, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Anatomical Location, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Risk-Factor, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Treatment Modality, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Anatomical Location, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Risk-Factor, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Treatment Modality, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Anatomical Location, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Risk-Factor, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
      • South Africa
      • North Africa
      • Central Africa

13. Competitive Landscape

  • Pfizer Inc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Merck and Co Inc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • GlaxoSmithKline plc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bayer AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Abbott Laboratories
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Baxter International Inc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Melinta Therapeutics LLC
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Atox Bio Inc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Wound Care Technologies Inc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • ConvaTec Group Plc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Smith and Nephew plc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Molnlycke Health Care AB
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • 3M Company
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Becton Dickinson and Company
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

14. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

15. References and Research Methodology

  • References
  • Research Methodology
  • About us